Daniel Carpenter

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Drug-review deadlines and safety problems
    Daniel Carpenter
    Department of Government, Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA
    N Engl J Med 358:1354-61. 2008
  2. ncbi Approval times for new drugs: does the source of funding for FDA staff matter?
    Daniel Carpenter
    Department of Government, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) . 2003
  3. ncbi A proposal for financing postmarketing drug safety studies by augmenting FDA user fees
    Daniel Carpenter
    Department of Government, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) . 2005
  4. ncbi Forcing pharmaceutical history into boxes
    Daniel Carpenter
    Harvard University, USA
    J Health Polit Policy Law 31:1015-9. 2006
  5. ncbi Staff resources speed FDA drug review: a critical analysis of the returns to resources in approval regulation
    Daniel Carpenter
    Harvard University, USA
    J Health Polit Policy Law 29:431-42; discussion 443-50. 2004
  6. ncbi Essay: the political logic of regulatory error
    Daniel Carpenter
    Department of Government, 1737 Cambridge St, CGIS N405, Harvard University, Cambridge, Massachusetts 02138, USA
    Nat Rev Drug Discov 4:819-23. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Drug-review deadlines and safety problems
    Daniel Carpenter
    Department of Government, Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA
    N Engl J Med 358:1354-61. 2008
    ..Critics have suggested that these deadlines may result in rushed approvals and the emergence of unanticipated safety problems once a product is in clinical use...
  2. ncbi Approval times for new drugs: does the source of funding for FDA staff matter?
    Daniel Carpenter
    Department of Government, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) . 2003
    ..NDA review times shortened by 3.3 months for every 100 additional FDA staff. The amount of funding for FDA staff appears to be a much more important influence on NDA review time than the source of funding...
  3. ncbi A proposal for financing postmarketing drug safety studies by augmenting FDA user fees
    Daniel Carpenter
    Department of Government, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) . 2005
    ..S. health care system; spread the burden of funding postmarketing safety studies among pharmaceutical sponsors; and help restore public, scientific, and professional confidence in the FDA and its user-fee system...
  4. ncbi Forcing pharmaceutical history into boxes
    Daniel Carpenter
    Harvard University, USA
    J Health Polit Policy Law 31:1015-9. 2006
  5. ncbi Staff resources speed FDA drug review: a critical analysis of the returns to resources in approval regulation
    Daniel Carpenter
    Harvard University, USA
    J Health Polit Policy Law 29:431-42; discussion 443-50. 2004
  6. ncbi Essay: the political logic of regulatory error
    Daniel Carpenter
    Department of Government, 1737 Cambridge St, CGIS N405, Harvard University, Cambridge, Massachusetts 02138, USA
    Nat Rev Drug Discov 4:819-23. 2005
    ..Here, we provide a theoretical discussion of the factors that could influence regulatory error, drawing on the Vioxx episode in particular as a possible example of error, and consider the implications for future regulatory policy...